Protalix Biotherapeutics, Inc. Announces Data On Oral Antitnf To Be Presented At Digestive Disease Week 2014 Meeting

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CARMIEL, Israel, April 23, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that preclinical data on oral antiTNF (PRX-106) was accepted for presentation at the Digestive Disease Week (DDW) Annual Meeting being held May 3-6 in Chicago, Illinois.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC